COMMUNIQUÉS West-GlobeNewswire

CV Sciences, Inc. Wins 2019 NEXTY Award
17/09/2019
Company’s industry-dominating hemp extract brand, PlusCBD Oil™ , wins Consumer Choice Award at Natural Products Expo East SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV [...]
Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™
17/09/2019
SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has [...]
Avricore Health and Clinart MENA Announce Interim Agreement for HealthTab™ + RASTR Network Middle East Expansion
17/09/2019
VANCOUVER, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce that it has signed a first stage agreement in the [...]
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
17/09/2019
WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to [...]
KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
17/09/2019
CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its [...]
Orphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event
17/09/2019
Orphazyme A/S Investor news No. 04/2019 Company Registration No. 32266355 Copenhagen, Denmark, September 17, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for [...]
Fujifilm Exercises License Option in GvHD
17/09/2019
MELBOURNE, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that FUJIFILM Corporation [...]
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology
17/09/2019
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which [...]
Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019
17/09/2019
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at [...]
Philips launches NightBalance, increasing therapy options for positional obstructive sleep apnea patients
17/09/2019
September 17, 2019 Clinically-validated sleep position treatment provides a comfortable, easy-to-use alternative for positional obstructive sleep apnea patients Updates include wireless connectivity and new mobile app [...]
CMR Surgical raises £195 million ($240 million) in Series C financing
17/09/2019
CMR Surgical Limited ("CMR Surgical" or the "Company") CMR Surgical raises £195 million ($240 million) in Series C financing ~ Europe’s largest private financing round in the medical technology sector ~ Financing will [...]
Immutep Announces Japanese Patent Grant for LAG525 Antibody
17/09/2019
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody molecules to LAG-3 [...]
Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain
17/09/2019
- CNTX-4975 Phase 3 clinical development program fully enrolled - - VICTORY-1 pivotal and VICTORY-3 open-label topline results expected in Q1 2020; VICTORY-2 pivotal results expected in Q3 2020 - BOSTON, Sept. 17, 2019 [...]
Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting
17/09/2019
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity
17/09/2019
PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
17/09/2019
BRISBANE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value [...]
Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise
17/09/2019
Global partnership spans Amgen’s entire portfolio of pipeline and marketed blood cancer therapies SEATTLE, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced it has [...]
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
17/09/2019
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
17/09/2019
NORCROSS, Ga., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have [...]

Pages